Adapted from the BU Department of Electrical and Computer Engineering's LaTeX template that can be found on the Mugar Library website. Prepared by Hanna Gerlovin in March 2018 based on earlier versions by Stephen Gildea, Paolo Gaudiano, Janusz Konrad, and Jonathan Polimeni.
Please make sure to check the current formatting guidelines, as they may change and this is not an official template.
"ModernCV" CV and Cover Letter
Version 1.11 (19/6/14)
This template has been downloaded from:
Xavier Danaux (firstname.lastname@example.org)
CC BY-NC-SA 3.0 (http://creativecommons.org/licenses/by-nc-sa/3.0/)
Chronic Myeloid Leukemia is a type of cancer that starts in certain blood-forming cells of the bone marrow. Interferon-\(\alpha\) was once the standard front-line treatment producing remission rates of only 28.3 percent in 1991. After the highly effective drugs first became available in 2001, survival rates have increased immensely. According to the American Cancer Society, one large study of CML patients treated with a drug called imatinib found that about 90 percent of them were still alive 5 years after starting treatment. While imatinib has changed the way oncologists treat CML, remission is common after extended gaps in treatment. In this paper, we will explore the long-term dynamics of CML under treatment through the use of use of theoretical and mathematical components. We closely base our methods upon the approach of Urszula Ledzewicz and Helen Moore. We will introduce our unique model and explain component selections, while we move towards understanding the optimal interactions of imatinib and interferon-\(\alpha\) against dormant and proliferating CML cells. Our future work involving optimal control dynamics will be briefly introduced and further solutions are currently ongoing.